Epigenome-wide association study of perceived discrimination in the Multi-Ethnic Study of Atherosclerosis (MESA)
- PMID: 39825881
- PMCID: PMC12118157
- DOI: 10.1080/15592294.2024.2445447
Epigenome-wide association study of perceived discrimination in the Multi-Ethnic Study of Atherosclerosis (MESA)
Abstract
Perceived discrimination, recognized as a chronic psychosocial stressor, has adverse consequences on health. DNA methylation (DNAm) may be a potential mechanism by which stressors get embedded into the human body at the molecular level and subsequently affect health outcomes. However, relatively little is known about the effects of perceived discrimination on DNAm. To identify the DNAm sites across the epigenome that are associated with discrimination, we conducted epigenome-wide association analyses (EWAS) of three discrimination measures (everyday discrimination, race-related major discrimination, and non-race-related major discrimination) in 1,151 participants, including 565 non-Hispanic White, 221 African American, and 365 Hispanic individuals, from the Multi-Ethnic Study of Atherosclerosis (MESA). We conducted both race/ethnicity-stratified analyses as well as trans-ancestry meta-analyses. At false discovery rate of 10%, 7 CpGs and 4 differentially methylated regions (DMRs) containing 11 CpGs were associated with perceived discrimination exposures in at least one racial/ethnic group or in meta-analysis. Identified CpGs and/or nearby genes have been implicated in cellular development pathways, transcription factor binding, cancer and multiple autoimmune and/or inflammatory diseases. Of the identified CpGs (7 individual CpGs and 11 within DMRs), two CpGs and one CpG within a DMR were associated with expression of cis genes NDUFS5, AK1RIN1, NCF4 and ADSSL1. Our study demonstrated the potential influence of discrimination on DNAm and subsequent gene expression.
Keywords: DNA methylation; Discrimination; epigenetics; psychosocial stress.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
References
MeSH terms
Grants and funding
- N01 HC095168/HL/NHLBI NIH HHS/United States
- R01 HL135009/HL/NHLBI NIH HHS/United States
- R01 HL141292/HL/NHLBI NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
- 75N92020D00002/HL/NHLBI NIH HHS/United States
- HHSN268201500003C/HL/NHLBI NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- 75N92020D00005/HL/NHLBI NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- R01 DK101921/DK/NIDDK NIH HHS/United States
- 75N92020D00001/HL/NHLBI NIH HHS/United States
- R01 HL101250/HL/NHLBI NIH HHS/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- 75N92020D00003/HL/NHLBI NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- 75N92020D00004/HL/NHLBI NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- 75N92020D00007/HL/NHLBI NIH HHS/United States
- HHSN268201500003I/HL/NHLBI NIH HHS/United States
- RF1 AG054474/AG/NIA NIH HHS/United States
- R01 HL126477/HL/NHLBI NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- 75N92020D00006/HL/NHLBI NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical